A Phase 3 Randomized Double-Blind Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy
Brief description of study
Eidos Therapeutics, Inc. (the Sponsor) is conducting a research study to see if an investigational study medicine named AG10, will help in the treatment of a rare disease called Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) that occurs when a protein, called transthyretin, is accumulated in the heart. This research study will check how safe and effective AG10 is in people with that disease. Investigational means the AG10 has not been approved by the US Food and Drug Administration (FDA).
Clinical Study Identifier: s18-02060
ClinicalTrials.gov Identifier: NCT03860935
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
